Susoctocog Alfa News
Susoctocog Alfa currently has 0 news articles, with 20 predicted indications.
This page combines the AI-predicted indications for Susoctocog Alfa with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Original indication: Treatment of bleeding episodes in patients with acquired haemophilia caused by antibodies to Factor VIII. Obizur is indicated in adults.
- Evidence level: L5
- Predicted indications (20):
- primary release disorder of platelets (99.9%)
- pseudo-von Willebrand disease (99.9%)
- Glanzmann thrombasthenia (99.9%)
- hemophilia (99.7%)
- acquired coagulation factor deficiency (99.6%)
- Scott syndrome (99.6%)
- acquired hemophilia (99.2%)
- bleeding diathesis due to a collagen receptor defect (99.2%)
- hemorrhagic disorder due to a constitutional thrombocytopenia (99.2%)
- congenital factor XIII deficiency (99.2%)
- adenosine deaminase deficiency (99.0%)
- factor XIII, A subunit, deficiency (98.8%)
- prothrombin deficiency (98.7%)
- congenital factor VII deficiency (98.4%)
- reticular dysgenesis (98.4%)
- hemorrhagic disorder due to a platelet anomaly (98.3%)
- severe combined immunodeficiency due to LCK deficiency (98.2%)
- platelet-type bleeding disorder (98.1%)
- fetal and neonatal alloimmune thrombocytopenia (97.7%)
- hemophilia A with vascular abnormality (97.5%)
Related News (0)
No related news yet. When news mentions this drug, it will be collected and shown here automatically.
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.